Steven Deeks is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 12 publications with 2,063 citations (h-index 8); ClinicalTrials.gov lists 20 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- CAR-T Cells for HIV Infection
Sponsor: Steven Deeks
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
5 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
46.9%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor18.9%Tivicay59%Dovato12%Isentress12%Juluca11%Isentress Hd6%Part D<11 patientsProtease Inhibitor10.3%Ritonavir36%Prezista26%Prezcobix23%Symtuza15%Part D<11 patients+ 3 more classes in this area
Cardiovascular
17.6%Statin10.8%Atorvastatin Calcium100%Part D≥17 patientsACE inhibitor3.9%Benazepril-Hydrochlorothiazide70%Lisinopril-Hydrochlorothiazide30%Part D<11 patients+ 2 more classes in this area
Nervous system
10.9%Gabapentinoids5.2%Gabapentin100%Part D<11 patientsSSRI4.6%Escitalopram Oxalate75%Trazodone Hcl26%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
12 NIH research awards on record, funded 1997–2026 per NIH RePORTER. The latest:
- Delaney AIDS Research Enterprise to Cure HIV
University of California, San Francisco
FY2026$4,998,395UM1AI164560 - A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses
University of California Los Angeles
FY2026$1,429,199U01AI172800 - Delaney AIDS Research Enterprise to Cure HIV
University of California, San Francisco
FY2025$4,998,394UM1AI164560
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
William Seeley, MD
University of California, San Francisco
Talmadge King, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”